According to a study co-led by researchers at MSK and published in @NatureMedicine, a new vaccine shows encouraging early results as a potential ready-made treatment for patients with pancreatic or colorectal cancer. Unlike individualized cancer vaccines, which are tailored to each patient, ready-made vaccines can be mass-produced and stored for immediate use. The vaccine, ELI-002 2P, targets tumors with mutations (or changes) in the KRAS gene, a driving force in many cancers, and is given after surgery to prevent or delay a return of cancer. “Having this type of vaccine would make it easier, faster, and less expensive to treat a larger number of patients,” says medical oncologist and pancreatic cancer specialist @EileenMOReilly, who co-led the trial. “This gives hope for people with pancreatic and colorectal cancer who have been out of effective treatments when their disease returns.” Learn more: bit.ly/45PS4ti